Disease Overview：Hepatocellular Carcinoma（HCC）
Hepatocellular carcinoma (HCC), the most common primary liver malignancy, typically arises in the setting of chronic liver disease—most frequently due to hepatitis B or C infection, alcohol-related cirrhosis, or non-alcoholic steatohepatitis (NASH). Early-stage HCC may be asymptomatic; diagnosis often relies on surveillance imaging (contrast-enhanced ultrasound, multiphasic CT, or MRI) and serum alpha-fetoprotein (AFP) assessment. Treatment strategy is highly stage-dependent: curative options include surgical resection, liver transplantation, and local ablation (e.g., radiofrequency or microwave ablation); intermediate-stage disease is commonly managed with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE); advanced cases may benefit from systemic therapies such as tyrosine kinase inhibitors (e.g., sorafenib, lenvatinib) or immune checkpoint inhibitors (e.g., atezolizumab + bevacizumab). Prognosis correlates strongly with tumor burden, liver function (Child-Pugh score), and performance status.
China offers distinct advantages for HCC management: its tertiary hospitals—especially those affiliated with top academic centers like Peking Union Medical College Hospital and Zhongshan Hospital (Fudan University)—house internationally trained hepatobiliary oncologists and multidisciplinary tumor boards with extensive experience in complex hepatic resections and living-donor liver transplantation. Advanced technologies—including real-time intraoperative ultrasound, robotic-assisted surgery, and next-generation sequencing for molecular profiling—are widely integrated into clinical pathways. Clinical outcomes align closely with global benchmarks: five-year survival after resection for early-stage HCC exceeds 60% in high-volume centers, and TACE response rates consistently surpass 70%. Crucially, treatment costs in China are typically 40–60% lower than in the US or Western Europe—without compromising quality—making comprehensive care, including diagnostics, surgery, and follow-up, significantly more accessible. As a dedicated medical tourism agency, we facilitate seamless access for international patients: verifying hospital credentials, coordinating appointments with specialist teams, providing transparent, all-inclusive pricing (with no hidden fees), arranging visas and accommodation, and offering multilingual case management from initial consultation through post-treatment recovery support.
Hepatocellular Carcinoma: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Hepatocellular Carcinoma (HCC)
Non-Surgical / Conservative / Medication Options
*Indicated for unresectable, advanced, or palliative-stage HCC; requires Child-Pugh A/B liver function and ECOG 0–2.*
- •Systemic Therapy (1st-line)
- Lenvatinib (12 mg/day): ¥12,600/month → $1,760 - Atezolizumab + Bevacizumab (IV q3w): ¥28,500/cycle → $3,980
- •Supportive & Monitoring Costs
- Abdominal MRI (contrast-enhanced, every 3 months): ¥2,800 → $390 - CT-guided biopsy (if diagnosis uncertain): ¥1,600 → $225
Surgical / Procedural / Interventional Options
*Eligibility: Single tumor ≤5 cm or ≤3 tumors each ≤3 cm; no macrovascular invasion; Child-Pugh A; MELD score <10.*
- •Liver Resection (Open/Laparoscopic)
- Preoperative workup (CT/MRI + ECG + pulmonary function + coagulation panel): ¥3,100 → $435
- •Transarterial Chemoembolization (TACE)
- Drug-eluting bead TACE (DEB-TACE): ¥26,000/session → $3,630
- •Radiofrequency Ablation (RFA) / Microwave Ablation (MWA)
- Includes ultrasound/CT guidance and anesthesia
Special / Complex Condition Options
- •Bridge-to-Transplant (for waitlisted patients)
- •Portal Vein Tumor Thrombus (PVTT)
- •Child-Pugh B/C or decompensated cirrhosis
Quick Selection Guide
- •Early-stage, fit patient (<70 y, no comorbidities): Resection — highest 5-year survival (60–70%), cost-effective long-term.
- •Intermediate-stage (multinodular, preserved liver function): TACE — median OS 20–25 months; optimal balance of efficacy and affordability ($2,590/session).
- •Advanced-stage (extrahepatic spread, ECOG 1–2): Atezolizumab + Bevacizumab — superior OS vs. sorafenib; justified despite higher monthly cost ($3,980/cycle) due to response durability.
- •Elderly (>75 y) or frail with comorbidities: Lenvatinib monotherapy — oral convenience, lower toxicity burden ($1,760/month), avoids procedural risks.
- •Child-Pugh B cirrhosis with small tumor: MWA under ultrasound guidance — minimally invasive, preserves hepatic reserve ($1,790–$2,120).
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Hepatocellular Carcinoma Medical Vacation Packages
Curated transparent all-inclusive packages combining Hepatocellular Carcinoma treatment with China top medical destinations:
